The London Biotechnology Show is making a significant return for its second annual edition, building on the remarkable success of its inaugural event that drew over 3,000 attendees representing 1,500 companies. The expanded #LBS25 promises to be a transformative platform for biotechnology innovation, featuring a substantial 4,000 square meter exhibition floor and an enhanced lineup of industry leaders.
Expanded Exhibition and Industry Participation
The 2025 edition has already secured participation from numerous industry giants and innovative companies. Leading biotech organizations joining the show include Discovery Park, Thistle Scientific, Haier Biomedical UK Ltd, Ellab, Mathys & Squire, Cool Repair System, Homogenising Systems Ltd, Merck, nNano, ZAGENO, and UPG International.
The exhibition floor will spotlight additional innovative companies such as Stratagem IPM, LI-Cor Bioscience Ltd, Restore Harrow Green, NIHR, FORMULATRIX, Clarity Compliance Solutions, Brookhouse, BRAND Scientific, Synbiosis, LAUDA Technology, Carterra, ProteoGenix, Life4sciences, Adelphi Healthcare Packaging, IKA, Appleton Woods, Firefinch Software, Integra Biosciences, Exeter Science Park, Miltenyi Biotec, Sterilem Bioscience, Eppendorf, Bishop Simon, LS Scientific, Guardtech Group, Orion GXP Consulting, Fieldfare Consulting, Oxartis, All Med Pro, and INDICRO.
Strategic Networking Through Hosted Buyer Programme
Recognizing the critical importance of collaboration in driving industry advancement, #LBS25 has introduced a Hosted Buyer Programme as one of its key highlights. This initiative serves as an ideal platform for connecting buyers seamlessly with participating sponsors and exhibitors through pre-arranged one-to-one meetings. The tailored matchmaking approach enables biotech professionals to expand their networks, discover complementary solutions, and establish valuable partnerships that can drive future business growth.
Distinguished Speaker Lineup and Conference Program
The conference features an exceptional lineup of speakers from leading organizations, promising to deliver thought-provoking keynote speeches, dynamic panel discussions, and interactive sessions. Notable participants include Andrew Miles, Multicultural Executive & Leader in Life Sciences and Technology at Google; Jakob E. Larsen, Target Discovery Project Director at Novo Nordisk; Thomas Balkizas, Senior Director Life Sciences at Microsoft; Dr Nicole Mather, Health & Life Sciences Leader at IBM; and Rohit Dayama, Client Partner, Life Sciences at Cognizant.
Additional distinguished speakers include Dr James Duboff, Strategic Partnerships Director at Genomics England; Mark Davies, Chief Health Officer at IBM; Prof. Zulfiqur Ali, Director of Academic Research and Innovation Partnerships at Teesside University; Professor Jon Dawson, Director of the Centre for Human Development, Stem Cells and Regeneration at University of Southampton; and Dr. Sharib Ali, Lecturer/Researcher in AI for Healthcare at University of Leeds.
The program also features Prof. Darius Widera, Professor of Stem Cell Biology and Regenerative Medicine at University of Reading; Linh TB Nguyen, Lecturer in Biomaterials and Allied Subjects at UCL; Anna Wilbrey-Clark, Senior Staff Scientist at Wellcome Sanger Institute; Dr Stephen Ward, Chief Manufacturing Officer at Cell and Gene Therapy Catapult; and Phil Brown, Director, Technical and Regulatory at Association of British Healthcare Industries Limited.
Cutting-Edge Topics and Innovation Focus
Attendees will have the opportunity to explore diverse cutting-edge topics in biotechnology, including gene editing, pharmaceuticals, regenerative medicine, agriculture, bioinformatics, medical devices, biomedical engineering, biotechnology in agriculture, and the latest developments in digital health. The conference program not only delves into emerging trends but also provides actionable strategies for professionals shaping the future of biotechnology.
The show will feature representatives from major pharmaceutical and technology companies including Bayer Pharmaceuticals, the Medicines and Healthcare products Regulatory Agency, Genomics England, AstraZeneca, Roche Information Solutions, and Pfizer, ensuring comprehensive coverage of industry perspectives and innovations.
Building on Previous Success
The inaugural London Biotechnology Show established itself as a major industry event with prominent speakers from companies such as Microsoft, the UK Health Security Agency, AltruBio Inc., Axia Medicine, AstraZeneca, Eli Lilly and Company, Roche, MENARINI Group, and Deep Science Ventures. The event's success was further amplified by the presence of esteemed media entities including the BBC, Associated Press, Bloomberg, Newsweek, Wired, Globaldata, and Raconteur, which enhanced its global reach and impact.
The expanded format for 2025 demonstrates the growing importance of biotechnology innovation and the industry's need for platforms that facilitate meaningful connections between innovators, investors, and industry leaders. The combination of exhibition space, strategic networking opportunities, and comprehensive conference programming positions #LBS25 as a critical event for professionals seeking to stay at the forefront of biotechnology advancement.
